Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation-Reference-Cited by-同舟云学术

Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation

Published:2016-04-04 Issue:8 Volume:51 Page:1082-1086
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Boudin L,Gonçalves A,Sabatier R^ORCID,Moretta J,Sfumato P,Asseeva P,Livon D,Bertucci F,Extra J-M,Tarpin C,Houvenaegel G,Lambaudie E,Tallet A,Resbeut M,Sobol H,Charafe-Jauffret E,Calmels B,Lemarie C,Boher J-M,Viens P,Eisinger F,Chabannon C^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt201682.pdf

Reference42 articles.

1. Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117–1130.

2. King M-C, Marks JH, Mandell JB,, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302: 643–646.

3. Moynahan ME, Chiu JW, Koller BH, Jasin M . Brca1 controls homology-directed DNA repair. Mol Cell 1999; 4: 511–518.

4. Moynahan ME, Pierce AJ, Jasin M . BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001; 7: 263–272.

5. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S et al. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol 2011; 29: 3214–3223.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study;Breast Cancer Research and Treatment;2022-02-22

2. Cytotoxic and targeted therapy for BRCA1/2-driven cancers;Hereditary Cancer in Clinical Practice;2021-08-28

3. Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors;World Journal of Clinical Oncology;2021-07-24

4. Outcomes of Bone Marrow Transplantation;Contemporary Bone Marrow Transplantation;2021

5. Systemic Therapies of Young Breast Cancer Patients at High Genetic Risk;Breast Cancer in Young Women;2020